Mortaliteit en hospitalisaties bij HFpEF versus HFrEF: vergelijkende analyse

INTRODUCTION: The global burden of heart failure (HF) is rising, with a shift towards more cases of heart failure with preserved ejection fraction (HFpEF). Given evolving epidemiology, an updated assessment of outcome differences between HFpEF and heart failure with reduced ejection fraction (HFrEF) is needed. This systematic review and meta-analysis aimed to provide a contemporary, large-scale comparison of clinical outcomes between HFpEF and HFrEF. METHODS: A systematic review and meta-analysis were conducted to compare all-cause mortality, cardiovascular (CV) mortality, and HF hospitalizations in HFpEF (EF: >50%) and HFrEF (EF: <40%). Risk ratios (RR) and maximally adjusted hazard ratios (HR) with 95% confidence intervals (CI) were pooled using random-effects models. Additional analyses included prior HF hospital admissions, in-hospital mortality, and length of hospital stay. RESULTS: A total of 101 studies were included. HFpEF patients had lower all-cause mortality [RR: 0.78; 95% CI: 0.69-0.88; P < .001; adjusted HR: 0.71; 95% CI: 0.62-0.80; P < .001; 112 vs 148 per 1000 patient-years (PY)], CV mortality [RR: 0.64; 95% CI: 0.53-0.79; P < .001; adjusted HR: 0.65; 95% CI: 0.56-0.75; P < .001; 73 vs 110 per 1000 PY], and HF hospitalizations [RR: 0.75; 95% CI: 0.63-0.91; P = .003; adjusted HR: 0.87; 95% CI: 0.78-0.98; P = .02; 171 vs 225 per 1000 PY] compared to HFrEF. CONCLUSION: HFpEF patients experience lower mortality and hospitalization risks than HFrEF patients, even after adjustment for confounders. However, high absolute event rates in HFpEF highlight the need for effective treatment strategies to improve outcomes.PROSPERO registration ID: CRD42024619499.